Boyu Capital is a private equity firm that invests in consumer, retail, media and technology, healthcare, and financial services sectors.
Business Model: B2C
Revenue: $5M
Employees: 11-50
Address: 88 Queensway
City: Hong Kong
State: other
Zip:
Country: HK
Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2021 | J&a;T Express | Private Equity Round | 2B |
12/2020 | SciNeuro | Series A | 100M |
11/2017 | Berry Oncology | Series A | 121.2M |
1/2019 | Yimidida | Series D | 266.1M |
10/2021 | WT Microtech Medical | Series E | 153M |
5/2018 | Brii Biosciences | Venture Round | 260M |
5/2013 | Berry Genomics | Series B | 14.7M |
5/2018 | China Chengxin Credit | Series A | 0 |
8/2021 | MediTrust Health | Series C | 0 |
3/2020 | Yuanfudao | Series G | 1B |
3/2020 | Pinduoduo | Post-IPO Equity | 1.1B |
6/2019 | Waterdrop | Series C | 144.6M |
4/2021 | Adcentrx Therapeutics | Series A | 50M |
9/2022 | Animoca Brands | Convertible Note | 110M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
5/2018 | CStone Pharmaceuticals | Series B | 260M |
11/2021 | Positive Sequence Biology | Series A | 0 |
1/2021 | 4Paradigm | Series D | 0 |
3/2020 | Yatsen Holding | Series D | 240M |
6/2022 | Frontera Therapeutics | Series B | 0 |
11/2021 | Edge Medical Robotics | Series C | 0 |
1/2021 | Lalamove | Series F | 1.5B |
8/2021 | Abogen Biosciences | Series C | 0 |
1/2019 | Antengene Corporation | Series B | 0 |
6/2021 | ArriVent Biopharma | Series A | 81M |
2/2022 | ArriVent Biopharma | Series A | 69M |
12/2021 | Jinke | Post-IPO Equity | 478.6M |
6/2014 | COFCO | Post-IPO Equity | - |
12/2022 | ArriVent Biopharma | Series B | 0 |
11/2020 | D3 Bio | Series A | 200M |
2/2014 | LY.com | Series C | 82.3M |
6/2022 | Evat Master | Series A | 0 |
7/2020 | Antengene Corporation | Series C | 97M |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
8/2018 | KLOOK | Series D | 200M |
12/2021 | Recurrent.ai | Venture Round | 38M |
12/2019 | Kuaishou Technology | Series F | 3B |
8/2021 | MediTrust Health | Series C | 308.3M |
11/2018 | NetEase Cloud Music | Series B | 600M |
7/2018 | Trax | Series D | 0 |
2/2018 | Viela Bio | Series A | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Vision Medicals | Series D | 47M |
8/2021 | Zeekr | Series A | 500M |
8/2020 | Yuanfudao | Series G | 1.2B |
7/2018 | Curon Biopharma | Series A | 150M |
7/2018 | MEGVII | Series D | - |
2/2017 | iQiyi | Series G | 1.5B |
8/2021 | Pulse Medical Technology | Series C | 0 |
9/2018 | LianLian Pay | Venture Round | 146.6M |
9/2021 | XSKY Data Technology | Series E | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
6/2021 | RecBio | Series C | 156.3M |
3/2022 | MoreSec | Series D | 0 |
1/2021 | KLOOK | Series E | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
9/2019 | Chengjia Apartment | Series A | 300M |
6/2022 | Frontera Therapeutics | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | Recurrent.ai | Venture Round | 0 |
12/2021 | Jinke | Post-IPO Equity | 0 |
11/2021 | Vision Medicals | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|